Category:
Active Pharmaceutical Ingredients
CAS NO:
1611493-60-7
Standard:
In-house Standards,
Bictegravir is a novel integrase inhibitor developed by Gilead Sciences scientists. In vitro and clinical results were produced by Gilead in the summer of 2016. As of June 2016, Bictegravir was used as a single tablet regimen in combination with tenofovir alafinamide (TAF) and emtricitabine (FTC) for the treatment of hiv-1 infection.
Indication: HIV-1 infection
All the products under the patent are only for R&D use.
Patent from Gilead Sciences, expiry date(The U.S):Dec.19,2033